Carlisle Companies Inc (CSL)

101.44
7.10 6.50
NYSE : Consumer Goods
Prev Close 108.54
Open 103.35
Day Low/High 100.78 / 106.27
52 Wk Low/High 98.22 / 116.40
Volume 1.84M
Avg Volume 455.50K
Exchange NYSE
Shares Outstanding 64.59M
Market Cap 7.05B
EPS 3.90
P/E Ratio 28.51
Div & Yield 1.40 (1.30%)

Latest News

Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

- AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A

Improving Access To Lifesaving Treatments For Bleeding Disorders In The Developing World

Improving Access To Lifesaving Treatments For Bleeding Disorders In The Developing World

- CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

CSL Behring Sponsors the First Network of its Kind on the African Continent

CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

CSL Behring's Local Empowerment for Advocacy Development Grant helps rare disease patient groups and patients protect access to lifesaving therapies.

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

CSL Behring Sponsors the First Network of its Kind on the African Continent

Carlisle Companies To Announce 1st Quarter Results On April 27, 2017

Carlisle Companies To Announce 1st Quarter Results On April 27, 2017

Carlisle Companies Incorporated (NYSE:CSL) will release first quarter 2017 results on Thursday, April 27, 2017 after the market closes.

New England Journal Of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients

New England Journal Of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients

- Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied

Largest Ever CIDP Clinical Study Completed

Largest Ever CIDP Clinical Study Completed

PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy

Carlisle Companies Appoints Robert M. Roche Vice President And Chief Financial Officer Effective February 15, 2017

Carlisle Companies Appoints Robert M. Roche Vice President And Chief Financial Officer Effective February 15, 2017

Carlisle Companies Incorporated (NYSE:CSL) is pleased to announce the appointment of Robert M.

Carlisle Reports Fourth Quarter And Full Year 2016 Results

Carlisle Reports Fourth Quarter And Full Year 2016 Results

Carlisle Companies Incorporated (NYSE:CSL) reported record net sales of $893.

Carlisle Companies Declares Regular Quarterly Dividend

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

Carlisle Companies Acquires Arbo Holdings Limited

Carlisle Companies Acquires Arbo Holdings Limited

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Arbo Holdings Limited, a leading provider of sealants, coatings and membrane systems used by architects and contractors for waterproofing and...

Short Interest Falls 26% For CSL

Short Interest Falls 26% For CSL

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 460,234 share decrease in total short interest for Carlisle Companies Inc. , to 1,303,008, a decrease of 26.10% since 12/15/2016.

Carlisle Companies Acquires San Jamar

Carlisle Companies Acquires San Jamar

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of San Jamar, Inc.

AFSTYLA®, For Haemophilia A, Receives European Commission Approval

AFSTYLA®, For Haemophilia A, Receives European Commission Approval

- CSL Behring's AFSTYLA is the first and only single-chain therapy for haemophilia A

Carlisle Companies To Announce 4th Quarter Results On February 9, 2017

Carlisle Companies To Announce 4th Quarter Results On February 9, 2017

Carlisle Companies Incorporated (NYSE:CSL) will release fourth quarter 2016 results on Thursday, February 9, 2017 after the market closes.

CSL CEO Says Holistic Approach To Business Is Essential To Corporate Sustainability, The Company's Value Chain And Patients

CSL CEO Says Holistic Approach To Business Is Essential To Corporate Sustainability, The Company's Value Chain And Patients

The global biotherapeutics company released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.

Carlisle Crew In La Gomera Preparing For The Race. L-R: Matt Brown, Alex Simpson, Angus Collins, Jason Caldwell

Carlisle Crew In La Gomera Preparing For The Race. L-R: Matt Brown, Alex Simpson, Angus Collins, Jason Caldwell

Carlisle Companies Incorporated (NYSE:CSL) announced that the Crew of the American Spirit will begin to row across the Atlantic Ocean on December 14 in the Atlantic Challenge, known as the "World's Toughest Row.

CSL Behring Presents New Phase III Analysis Of IDELVION® For Hemophilia B At The 2016 American Society Of Hematology Annual Meeting

CSL Behring Presents New Phase III Analysis Of IDELVION® For Hemophilia B At The 2016 American Society Of Hematology Annual Meeting

- Analysis of clinical trial efficacy results and estimated factor IX levels suggests that patients who maintain factor IX activity levels above 5 and 10 percent have significantly reduced bleeding risk

CSL Behring Presents Positive Results From The CSL112 AEGIS-I Phase 2b Trial

CSL Behring Presents Positive Results From The CSL112 AEGIS-I Phase 2b Trial

Study Meets Co-Primary Endpoints of Hepatic and Renal Safety and Demonstrates Proof of Mechanism

AFSTYLA®, For Haemophilia A, Receives Positive Opinion From European Medicines Agency CHMP

AFSTYLA®, For Haemophilia A, Receives Positive Opinion From European Medicines Agency CHMP

-- CHMP positive opinion moves AFSTYLA one step closer to approval in the European Union

Carlisle Companies Declares Regular Quarterly Dividend

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

Carlisle Companies To Present At Baird Industrial Conference In Chicago On November 8

Carlisle Companies To Present At Baird Industrial Conference In Chicago On November 8

D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at the Baird Industrial Conference at the Four Seasons Hotel in Chicago, IL at 10:00 a.

Jim Cramer's 'Mad Money' Recap: Credibility Is the Most Valuable Currency for Investors

Jim Cramer's 'Mad Money' Recap: Credibility Is the Most Valuable Currency for Investors

Jim Cramer names companies with credibility, like NXPI and AAPL, and those that don't have it, including FIT.